Acute and chronic graft-versus-host disease (GVHD) remains a major complication of allogeneic transplantation using reduced-intensity conditioning regimens, and it is important that strategies that might reduce this risk are explored. 1 We therefore read with interest the paper by Passweg et al 2 describing a high incidence of graft failure in patients transplanted with T-cell depleted (TCD) allogeneic peripheral blood stem cells using a reduced-intensity preparative regimen. Although it is accurate to state, as they do, that there is limited experience of the impact of TCD on engraftment in patients receiving such regimens, there are now a number of publications reporting high rates of durable stem cell engraftment using fludarabine-based nonmyeloablative regimens in conjunction with either in vivo or ex vivo TCD. [3] [4] [5] [6] [7] In a series of 44 patients who received in vivo alemtuzemab in conjunction with a fludarabine/melphalan conditioned sibling allograft, the University College Hospital group reported donor engraftment in 42 3 and the same group observed primary graft failure in fewer than 5% of 42 recipients of unrelated donor allografts using a similar regimen. 4 In addition, three groups have reported donor engraftment in recipients of ex vivo TCD sibling or unrelated donor transplants using a fludarabine-based conditioning regimen. Of a total of 29 patients, donor stem cell engraftment was documented in all but three patients. [5] [6] [7] It is clear that the factors determining engraftment of allogeneic stem cells are multiple and complex including, in addition to the T-cell content of the donor stem cell inoculum, the degree of HLA disparity between donor and recipient, the immunosuppressive property of the conditioning regimen, the stem cell dose transplanted and both the nature of the underlying haematological malignancy and the immunosuppressive quality of chemotherapy regimens used prior to transplantation. It is therefore of interest that the patients reported by Passweg et al, while receiving high stem cell doses, did not receive fludarabine as part of the conditioning regimen, and in addition included a number of patients with chronic myeloid leukaemia (CML) who, it must be presumed, received minimal chemotherapy prior to transplantation. It will therefore be important in future to analyse the impact of TCD on engraftment with reference to the precise composition of the preparative regimen as well as the nature of the underlying disease and previous therapy.
Thus, while the observations reported by Passweg are valuable, it is unwarranted to draw the conclusion, as they have, that TCD is necessarily associated with a high rate of graft failure in the context of reduced-intensity conditioning regimens. Indeed, this approach towards prophylaxis of GVHD remains of real interest in the management of patients with indolent haematologial malignancies such as CML or low-grade lymphoma, and in nonmalignant haematological disorders such as sickle cell disease and chronic granulomatous disease where reduced-intensity transplants hold such promise. 
